29 May 2019 - Officials from the US FDA's oncology offices say they plan to develop a glossary of patient-friendly terms and definitions for oncology clinical trial endpoints.

In a paper published earlier this month in The Oncologist, officials from FDA’s Oncology Center of Excellence and Office of Hematology and Oncology Products make the case for working with patients and patient advocacy groups to develop resources to help patients understand the complex and nuanced terminology they are often faced with when making treatment decisions.

“Patients are often left wondering where to start and where to go for understandable information, because medical terminology, specifically terminology surrounding cancer diagnosis and treatment, can be complex,” the officials write.

Read Regulatory Affairs Professional Society article